Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

861
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
861
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

1.0K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

289
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
289
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

381
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
381
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

384
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
384
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

423
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of outcomes associated with antipseudomonal beta-lactams for treatment of methicillin-susceptible <i>Staphylococcus aureus</i> bacteremia: a retrospective cohort analysis.

Therapeutic advances in infectious disease·2025
Same author

Safety of Extended Propofol Infusions in Critically Ill Pediatric Patients.

Cureus·2024
Same author

Impact of a Pediatric Emergency Medicine Pharmacist, Institutional Guideline, and Electronic Order Set on Empiric Antimicrobial Use for Febrile Neutropenia.

Pediatric emergency care·2023
Same author

Development of complexity categories for an investigational drug services complexity scoring tool to assess pharmacy effort in clinical trial initiation and maintenance.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2023
Same author

Pharmacy student self-assessment of strength of residency candidacy compared to clinical faculty.

Currents in pharmacy teaching & learning·2022
Same author

Strategies for Implementing Pediatric Dose Standardization: Considerations From the Vizient University Health System Consortium Pharmacy Network Pediatric Pharmacy Committee.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2022
Same journal

Ganciclovir Therapeutic Drug Monitoring in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same journal

Commentary on "Examining the Evidence Around Acetaminophen and Autism Risk".

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same journal

Sweet or Salty: Comparing Dextrose and Sodium Acetate Umbilical Arterial Catheter Fluids.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same journal

A Case of Prolonged Serotonin Toxicity After Fluoxetine Ingestion in an Adolescent Patient.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same journal

Efficacy and Safety of Tranexamic Acid in Pediatric Trauma: A Systematic Review and Meta-Analysis.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same journal

Heparin Resistance - A Reality or Fallacy.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
See all related articles

Related Experiment Video

Updated: Feb 28, 2026

Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.1K

Cannabinoids in Pediatrics.

Christopher T Campbell, Marjorie Shaw Phillips, Kalen Manasco

    The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG
    |June 23, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Medical marijuana use is increasing, prompting a need for pediatric guidance. This review provides healthcare providers with resources on cannabis compounds for safe pediatric recommendations.

    Keywords:
    CBD, cannabidiolcannabisepilepsypediatricspharmacy

    More Related Videos

    Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
    03:43

    Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

    Published on: August 22, 2025

    593
    Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
    05:13

    Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

    Published on: February 28, 2025

    766

    Related Experiment Videos

    Last Updated: Feb 28, 2026

    Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
    07:51

    Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

    Published on: August 1, 2025

    1.1K
    Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
    03:43

    Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

    Published on: August 22, 2025

    593
    Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
    05:13

    Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

    Published on: February 28, 2025

    766

    Area of Science:

    • Pharmacology
    • Public Health
    • Pediatrics

    Background:

    • Medical marijuana and cannabis-derived products are increasingly popular.
    • Over 40 states have enacted legislation for medical marijuana or cannabidiol (CBD) products.
    • Healthcare providers are increasingly encountering patients using cannabis for various conditions.

    Purpose of the Study:

    • To review the history of marijuana use and legislation in the United States.
    • To compile current medical literature on cannabis-derived compounds.
    • To equip pediatric healthcare providers with resources for safe and appropriate cannabis recommendations for children and parents.

    Main Methods:

    • Literature review of historical data on marijuana use and legislation.
    • Systematic review of available medical literature on cannabis and its derivatives.
    • Synthesis of information to guide pediatric healthcare providers.

    Main Results:

    • The use of medical marijuana and cannabis-derived products is widespread and growing.
    • Legislation regarding cannabis products varies significantly across the United States.
    • There is a growing need for evidence-based guidance on pediatric cannabis use.

    Conclusions:

    • Pediatric use of cannabis-derived compounds requires special consideration due to ongoing debates and evolving research.
    • Healthcare providers need accessible resources to make informed recommendations for patients and parents.
    • Further research is essential to establish clear guidelines for the safe and effective use of cannabis in pediatric populations.